HPV 16 and 18 accounted together for a 72.4% of positive cases, with no statistically significant changes in their relative contributions over the last decades.
In 94% of cervical adenocarcinomas we identified at least one of the two HPV types included in the current vaccines (HPV 16/18). Results suggest a major impact of HPV vaccines on reduction of ICC burden in Spain in the HPV vaccinated cohorts.
2012-02-13
Eng.
Gynecologic oncology
IDIBELL, Institut Català d'Oncologia - Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain. lalemany [at] iconcologia.net
Gynecol Oncol. 2012 Mar;124(3):512-7
© Galenicom 1999-2013